Compound Radar

Lantheus Holdings, Inc. (LNTH) Stock Analysis

Price $100.44
Market cap $6.56B
Next earnings Nov 5, 2026
Entry status Watch $86.12–$91.44

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

70
70/100 High Quality
  • Financial Health 75
  • Profitability 60
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 70/100 — High Quality

Strongest Cash Flow 80/100
Softest Profitability 60/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Lantheus Holdings, Inc. 70/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 24.03
  • Forward P/E 15.75
  • EV/Revenue 4.26

Profitability

  • Revenue Growth 2.7%
  • Gross Margin 60.1%
  • Operating Margin 25.8%
  • Net Margin 17.7%
  • ROE 22.2%

Financial strength

  • Cash $593.30M
  • Debt $624.96M
  • Net Cash $-31.66M
  • Free Cash Flow $348.64M
  • Current Ratio 3.06

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Lantheus Holdings, Inc. (LNTH).

View Methodology & FAQ →